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ABSTRACT
New tools are required to expedite the development of
an effective vaccine against the blood-stage infection
with the human malaria parasite Plasmodium falci-
parum. This work describes the assessment of the
ADRB assay in a mouse model, characterizing the func-
tional interaction between antimalarial serum antibod-
ies and FcRs upon neutrophils. We describe a reproduc-
ible, antigen-specific assay, dependent on functional FcR
signaling, and show that ADRB activity is induced equally
by IgG1 and IgG2a isotypes and is modulated by blocking
FcR function. However, following immunization of mice
with the blood-stage vaccine candidate antigen MSP142,
no measurable ADRB activity was induced against PEMS
and neither was vaccine efficacy modulated against Plas-
modium yoelii blood-stage challenge in /mice com-
pared with WT mice. In contrast, following a primary, non-
lethal P. yoelii parasite challenge, serum from vaccinated
mice and nonimmunized controls showed anti-PEMS
ADRB activity. Upon secondary challenge, nonimmunized
/mice showed a reduced ability to control blood-stage
parasitemia compared with immunized /mice; how-
ever, WT mice, depleted of their neutrophils, did not lose
their ability to control infection. Thus, whereas neutrophil-
induced ADRB against PEMS does not appear to play a
role in protection against P. yoelii rodent malaria, induc-
tion of ADRB activity after challenge suggests that anti-
gen targets of anti-PEMS ADRB activity remain to be es-
tablished, as well as further supporting the observation
that ADRB activity to P. falciparum arises following re-
peated natural exposure. J. Leukoc. Biol. 95: 369–382;
2014.
Introduction
Throughout the 20th century, vaccination has proved to be
the most successful and cost-effective strategy for fighting dis-
ease; however, highly efficacious vaccines against major global
health threats, such as malaria, remain elusive [1]. Subunit
vaccines against the blood stage of the malaria lifecycle,
whereby the parasite undergoes multiple rounds of invasion
into the host’s erythrocytes, followed by asexual replication,
have been a significant focus of preclinical vaccine-develop-
ment efforts. To date, the vast majority of work has focused on
two candidate antigens from the invasive Mz form of the para-
site: MSP1 and AMA1; however, the progression of these can-
didates into clinical trials has provided largely disappointing
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results [2–5]. The limited number of Plasmodium antigen tar-
gets studied to date can be attributed, in some part, to the
paucity of available preclinical assays with which candidate an-
tigens can be assessed for use in vaccine candidates [6], as well
as limited access to nonhuman primate models of P. falciparum
blood-stage infection [7]. The lack of such assays comes from
a relatively incomplete understanding of how antibody-medi-
ated protection is conferred in vivo in humans, as well as tech-
nical limitations. Whereas it is largely accepted that antibodies
are the key effectors of blood-stage immunity [8, 9], the mech-
anism(s) by which such antibodies act remain widely debated.
Currently the “gold standard” in vitro assay for assessing the
effectiveness of vaccine-induced or naturally acquired antibod-
ies against blood-stage parasites (the assay of GIA) measures
antibodies’ cell-independent ability to neutralize parasites and
thus, block their ability to invade or grow within erythrocytes
[10–12]. Whereas it is highly likely that antibody GIA-type
neutralization is an important effector mechanism for some
antimalarial antibodies, vaccine candidates selected on the ba-
sis of promising GIA induction have, so far, shown limited effi-
cacy in clinical trials. For example, the highest levels of GIA
yet induced in humans by vaccination was reported for an
AMA1 protein-based vaccine candidate. In this case, immu-
nized volunteers showed high levels of serum GIA (77% mean
at 4 mg/mL purified IgG) but failed to exhibit any significant
clinical efficacy against controlled human malaria infection
with homologous 3D7 clone parasites [4]. Intriguingly, the
same vaccine was reported to induce strain-specific efficacy in
a Phase IIb field trial in Malian children [13]; however, the
number of 3D7-type parasite infections was small, and it re-
mains unreported as to whether protection was associated with
in vitro GIA. Another vaccine based on MSP1 and adminis-
tered in the same AS02 proprietary adjuvant from GSK failed
to show efficacy in a Phase IIb field trial in Kenya [5]. This
field of vaccine development has thus been directed largely on
the results of GIA assays, with disappointing clinical results.
Consequently, there is an increasing realization of the need to
develop vaccines that also induce different antimalarial anti-
body effector functions and an urgent need for the develop-
ment of new assays to detect such responses.
The ability of cytophilic antibodies to initiate cellular im-
mune responses as a result of Fc-dependent signaling has also
attracted attention in the context of antimalarial blood-stage
immunity. An assay assessing ADCI describes monocytes as key
effectors in antibody-dependent antimalarial cellular activity
[14]. FcRIIa/CD32a and FcRIII/CD16 signaling activates
human monocytes to release TNF- in response to the op-
sonization of Mz by cytophilic IgG1 and IgG3 antibodies [15–
17]. Polyclonal antibodies that showed ADCI activity in vitro
were also reported to confer protection when passively trans-
ferred to nonimmune humans [9], although no causal link
was formally demonstrated between anti-Mz ADCI and protec-
tive outcome. Despite these reports, however, the ADCI assay
has been notoriously difficult to reproduce and as a result, has
not established itself as a mainstream tool for anti-Mz vaccine
candidate antigen screening. Nevertheless, the contribution of
FcRs to the mediation of blood-stage malaria immunity should
not be discarded. Whereas conflicting reports occur as to the
role of FcR-dependent mechanisms in protection against P.
yoelii rodent malaria [18, 19], IgG antibody-dependent FcR
activity has been shown to play an important role in control of
infections by Plasmodium berghei XAT [20] and P. berghei, trans-
genic for the PfMSP119 [21], whereas the inhibitory FcRIIb/
CD32b is reported to affect Plasmodium chabaudi parasite clear-
ance and disease outcome [22].
Whereas the role of monocytes as effectors of antibody Fc-de-
pendent anti-Mz activity remains under investigation, neutrophils
represent an alternative and plausible candidate cell population
for clearing blood-stage parasites, given their high phagocytic effi-
ciency and their ability to generate ROS. In particular, a fast
clearance of P. falciparum in Gabonese children has been corre-
lated with high ROS production [23]. Additionally, the ADRB
assay, which measures neutrophil ROS production in response to
opsonized Mz, has been associated recently with protection
against clinical malaria in an endemic population [24]. Con-
versely, assays measuring GIA in the serum of naturally exposed
humans have not established a clear association with clinical dis-
ease outcome, with studies being divided in their support for a
role of GIA in naturally acquired immunity [11]. The association
of ADRB with natural clinical protection provides a new opportu-
nity to assess a largely neglected mechanism by which antibodies
could be controlling blood-stage malaria infection. Here, we in-
vestigated the mechanisms of action underlying ADRB activity in
the mouse model and the contribution of ADRB activity in medi-
ating P. yoelii rodent malaria challenge outcome in MSP1-vacci-
nated and naive, nonimmunized mice.
MATERIALS AND METHODS
Animals and immunizations
All procedures were performed in accordance with UK Animals (Scientific
Procedures) Act Project License and were approved by the University of
Oxford Animal Care and Ethical Review Committee. Six- to 8-week-old WT
female BALB/c (H-2d), C57BL/6 (H-2b), and TO outbred mice were
sourced from Harlan UK (Oxon, UK). BALB/c / [25] and C57BL/6
CD32b/ (002848; The Jackson Laboratory, Bar Harbor, ME, USA) mice
were provided from the Queen’s Medical Centre (Nottingham, UK) and
bred at the Wellcome Trust Centre for Human Genetics, University of Ox-
ford (UK). Knockout mouse genotypes were confirmed by PCR [26, 27].
Mice were anesthetized with IsoFlo (Abbott Animal Health, Berkshire, UK)
before i.m. immunization in a total volume of 50 L, split equally between
each musculus tibialis, unless stated otherwise.
Vaccines and generation of antigen-specific sera
Human rAdHu5 and MVA vectors expressing the PyMSP142 [28] or the
PfMSP1 clinical vaccine construct PfM128 [29] have been described previ-
ously. The adenovirus vaccines ifu were measured as described previously
[26]. When used to immunize, AdHu5-PyMSP142 at 1.5  10
9 ifu or
AdHu5-PfMSP1 at 7  108 ifu and MVA at 1  107 pfu were formulated in
endotoxin-free, low-phosphate PBS (Gibco-Invitrogen, Life Technologies,
Paisley, UK) and administered 8 weeks apart (Ad-M). Serum was harvested
14 days following the MVA boost. The use of chimpanzee adenovirus sero-
type 63 and MVA expressing a transmission-blocking malaria vaccine candi-
date Pfs25 to raise Pfs25-specific antibody responses in the same manner
has been reported previously [30].
PyMSP119-, PyMSP133-, and PfMSP119 (3D7/ETSR allele)-GST fusion pro-
teins, as well as GST control, were produced in an Escherichia coli expression
system, as described previously [28, 29]. rPyMSP119, fused to IMX108 (mouse
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complement C4 binding protein) [31], was kindly provided by Dr. F. Hill
(Imaxio, Lyon, France). Generation of immune sera against PyMSP119, Ova,
and GST has been described previously. Briefly, BALB/c mice were immu-
nized with recombinant proteins using the following regimes, respectively:
three immunizations of 20 g PyMSP119-GST formulated in AdjuPhos adjuvant
(Brenntag Biosector, Frederikssund, Denmark) given at 3-week intervals (PPP)
or a single 20-g PyMSP119-GST in AdjuPhos immunization given 8 weeks af-
ter a 1.0  109 ifu AdHu5 prime (AP); three immunizations of 20 g Grade
VII Ova (Sigma-Aldrich, Dorset, UK) in available adjuvants at 3-week intervals
[32]; or one immunization of 5 g GST protein in Montanide ISA 720 [33].
Serum was harvested 14–17 days after final immunization.
P. falciparum Mz lysate
P. falciparum 3D7 clone parasites were maintained routinely in culture, as
described previously [34]. The supernatant of a 20-mL in vitro culture of P.
falciparum at 10% hematocrit and 10–15% parasitemia was harvested and
replaced daily and centrifuged at 830 g to pellet and discard RBCs. After
10 days, pooled supernatant was centrifuged at 1500 g for 25 min to pellet-
free Mz. The Mz pellet was washed twice in PBS and resuspended in 500
L PBS. The resulting suspension was vortexed vigorously and freeze-
thawed in aliquots to form a lysate. Anti-Mz immune sera were generated
by immunizing BALB/c mice s.c., once with 50 L Mz lysate formulated in
50 L CFA, followed by two further s.c. immunizations of 50 L Mz lysate
in 50 L IFA at 3-week intervals. Serum was harvested 21 days later.
Isotype-specific PfMSP119 mAb
PfMSP119-specific chimeric mouse IgG1 and IgG2a mAb against the C1
epitope were expressed in HEK293 and CHO cell lines as described previ-
ously [35]. Briefly, cells were cultured in hyperflasks for 17 days in selective
media [DMEM supplemented with 10% low IgG FBS (Life Technologies,
Carsbad, CA, USA), 1% penicillin/streptomycin (Sigma-Aldrich), 1% L-glu-
tamine (Sigma-Aldrich), 250 g/mL mycophenolic acid (Sigma-Aldrich),
12.5 g/mL xanthine (Sigma-Aldrich), 1/1000 vol/vol hygromycin (Sigma-
Aldrich; for IgG1), or 1/1000 vol/vol geneticin (Invitrogen, Life Technolo-
gies, Paisley, UK; for IgG2a)] before supernatant was collected. mAb IgG
was purified from media using protein G drip columns (Sigma-Aldrich),
according to the manufacturer’s instructions, and IgG concentrations were
determined using a ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
Mouse ADRB assay
Two methodologies were used to assess mouse PMN ADRB activity.
Recombinant protein-coated plates. PyMSP119-GST (100 L) or
PfMSP119-GST protein at 10 g/mL (unless otherwise stated) was adsorbed
onto Nunc opaque MaxiSorp 96-well plates at RT overnight. Plates were
then washed three times with PBS and blocked for 1 h with casein block
solution (Pierce, Fisher Scientific, Loughborough, UK) before a second
wash. Serum diluted 1:100 in PBS (100 L) (unless otherwise stated), or
epitope-matched anti-PfMSP119 mouse IgG1 and IgG2a mAb [35] at 8.3
g/mL were then added and incubated for 1 h at 37°C. Mouse neutrophils
were isolated from bone marrow extracted from the femurs and tibias of 6-
to 20-week-old BALB/c, C57BL/6, /, and CD32b/ mice using Percoll
(Sigma-Aldrich) density gradients and resuspended in neutrophil buffer
(HBSS, 1% glucose, 0.1% BSA) at 1  107 PMNs/mL [36]. Purified cells
were confirmed to be Ly6Cint and CD11b by flow cytometry, and purity
was assessed by Giemsa-stained slides. Within 2 min of a final wash of the
assay plate in PBS, 50 L isoluminol (Sigma-Aldrich; 0.04 mg/mL) and 50
L mouse cells at 1  107 PMNs/mL (unless otherwise stated) were added
to each well, and luminescence—in RLU—resulting from ROS, released by
PMNs reacting directly with isoluminol, was read each minute for 1 h using
a Varioskan Flash luminometer. To investigate the role of FcR signaling in
ADRB activity (see Fig. 2B), PMNs were incubated for 15 min at 4°C with
rat anti-mouse CD16/32 mAb (clone 93; eBioscience, Hatfield, UK) or con-
trol rat IgG (Sigma-Aldrich).
PyPEMS in solution. Two TO mice were inoculated i.p. with 100 L le-
thal P. yoelii strain YM pRBCs and monitored until blood-stage parasitemia
reached 30–50%. Blood was taken by cardiac puncture and cultured for 24
h at 8% hematocrit and 37°C to allow parasites to mature to late schizonts
[37]. Infected cells were then isolated on a 65% Percoll gradient [38],
washed, and resuspended in PBS at 1.8  105 schizonts/mL. These PEMS
were then frozen to lyse the RBCs and release the P. yoelii Mz. ADRB activ-
ity was assessed by adding 20 L PyPEMS and 5 L neat sera to each well
of a one-half area opaque 96-well plate (Pierce, Fisher Scientific) and incu-
bating at 37°C for 1 h before addition of neutrophils and isoluminol as
above. For antigen depletions (see Fig. 7), 5 L serum was incubated with
5 L PyMSP119-GST or PyMSP133-GST at 1 mg/mL for 1 h at RT before
incubation with Mz. This protocol was shown to be effective by ablation of
ADRB activity on PyMSP119-GST- and PyMSP133-GST-coated plates by the
respective antigen depletions (Supplemental Fig. 1).
For both assays, RLU readouts were indexed against a positive reference
serum from Ad-M PfMSP1-immunized, Ad-M PyMSP142-immunized, or
twice Py17XNL-challenged mice for the PfMSP1, PyMSP1, and PyPEMS as-
says, respectively. All readouts are thus calculated as a proportion of a stan-
dard positive control (see Results).
ELISA
Total IgG ELISAs were carried out using a standardized ELISA methodol-
ogy [39]. AUs were determined by comparison with a standard curve of
pooled sera from mice immunized with Ad-M PyMSP142, diluted twofold
down the plate starting from a 1:1000 dilution. OD405 was read using a
BioTek ELx800 microplate reader (BioTek, Bedfordshire, UK). Naive
mouse serum samples were negative for antigen-specific responses on all
plates (data not shown). Plates were developed until positive control sam-
ples reached an OD405 of 1.0, and this point was defined as 1 AU, with AU
read off of the resulting curve [39]. For mice receiving PPP or AP immuni-
zation, serum total IgG end-point ELISAs were carried out as described
previously [28]. End-point titers were defined as the dilution at which sam-
ple absorbance reached 3 sd greater than the OD405 for serum from a na-
ive mouse. A standard, positive serum sample and naive serum sample were
included as controls for each assay.
Antigen-specific IgG1 and IgG2a responses were also determined with a
standardized ELISA method, as described previously [32]. Briefly, 96-well
plates were coated with PyMSP119-IMX108 protein to avoid measuring re-
sponses to GST in mice immunized with PyMSP119-GST. Standard curves
were made with purified mouse IgG1 and IgG2a mAb (eBioscience) start-
ing at a concentration of 20 g/mL and diluted threefold. After blocking,
test serum was added in duplicate wells and incubated for 2 h before wash-
ing. Biotin anti-mouse IgG1 or IgG2a (Becton Dickinson, San Diego, CA,
USA) was then added for 1 h, followed by washing and incubation with
extravidin alkaline phosphatase (Sigma-Aldrich) for 30 min. Plates were
then developed using the same reagents as for total IgG ELISA and isotype
units, calculated as for total IgG AU.
Flow cytometry
Whole mouse blood was collected from tail veins into 200 L, 10 mM
EDTA in PBS and spleens harvested and processed as described previously
[40]. Briefly, spleens were crushed and passed through a 70-m cell
strainer before treatment with ACK lysis buffer to lyse RBCs. Whole
blood samples were also lysed in a similar manner. After washing, lym-
phocyte and splenocyte samples were resuspended in 200 L and 7 mL
PBS/BSA, respectively. The resulting cell suspensions (150 L) were sur-
face-stained for 30 min at 4°C with Alexa Fluor 700-labeled anti-CD11b
(clone M1/70), allophycocyanin-labeled anti-Ly6C (clone HK1.4), and Per-
CPCy5.5-labeled anti-CD8 (clone 53-6.7). Cells were then washed twice in
150 L PBS/BSA and resuspended in 200 L PBS/BSA. Samples were run
on an LSR II flow cytometer (BD Biosciences, San Jose, CA, USA) with
stopping gates set at 100,000 CD8 events for splenocyte samples and
10,000 CD8 events for lymphocyte samples. Granulocytes were gated by
forward- and side-scatter and neutrophils identified as the CD11b Ly6Cint
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granulocyte population (Supplemental Fig. 2). Data were analyzed using
FlowJo v8.8.7.
PMN
To deplete neutrophils, mice were injected i.p. with 0.5 mg 1A8 rat mAb
(Bio X Cell, West Lebanon, NH, USA) [41, 42], 1 day before and 3 days
after challenge with P. yoelii pRBCs. Control animals were given 0.5 mg
control rat IgG (Sigma-Aldrich) i.p. at the same time-points. Depletion was
monitored at 1 and 7 days after challenge in the blood and spleen of an
additional group of animals, as above by flow cytometry. The percentage
depletion attained was calculated using the number of PMNs (Ly6Cint
CD11b granulocytes; Supplemental Fig. 2B) per lymphocyte (Supplemen-
tal Fig. 2A) in a mouse treated with control rat IgG compared with the
number of PMNs/lymphocyte in a 1A8-treated mouse as follows:





Lethal (strain YM) and nonlethal (strain 17XNL) P. yoelii challenges were
carried out as described previously [28]. Experimental animals were in-
fected by i.v. injection with 104 or 106 pRBCs. Blood-stage parasitemia, cal-
culated as percentage of infected RBCs, was monitored from Day 3 post-
challenge by microscopic examination of Giemsa-stained thin blood
smears. Mice whose blood smears had no observable parasites in 50 fields
of view were considered uninfected, and those that reached the humane
end-point of 50%-infected RBCs were culled.
Statistical analysis
All statistical analysis was carried out using Prism v.5.03 (GraphPad Soft-
ware, La Jolla, CA, USA). Comparisons between two groups were con-
ducted using Mann-Whitney test or Wilcoxon matched-pairs signed-rank
test when data were paired. Comparisons among three or more groups
were assessed by means of a Kruskal-Wallis test (independent groups) or a
Friedman test (paired data/repeated measures of samples). Post hoc
Dunn’s multiple comparison tests were used to identify contributing factors
to significant Kruskal-Wallis or Friedman tests. Two-way ANOVAs were used
to assess intra- and interassay variability by analyzing the effect of sample
and that of assay run respectively, as well as determining each factor’s rela-
tive contribution to measured R2. Parasitemia was analyzed using an AUC
analysis, and correlations between ELISA titer and ADRB activity were
tested using Spearman rank correlation. Statistical significance was consid-
ered at P  0.05.
RESULTS
ADRB assay development
Neutrophil respiratory burst activity (NADPH oxidase activa-
tion), induced by mouse sera, was assessed initially using neu-
trophils enriched from mouse bone marrow and recombinant
protein coated onto a plate, according to published methodol-
ogies [19, 43]. To establish the assay, sera from BALB/c mice,
immunized with Ad-M PfMSP1, were used, which were known
to be reactive against PfMSP119-GST protein [29]. Percoll sep-
aration was used to enrich neutrophils to 95%, as deter-
mined by examination of Giemsa-stained slides. The isolated
cell population was confirmed as Ly6Cint CD11b granulocytes
by flow cytometry (Fig. 1A). Results in a previous study were
indexed according to a positive reference serum, which was
included each time the assay was run [24]. This approach was
also applied here, using a pool of positive antigen-specific se-
rum (see Materials and Methods). As such, results are pre-
sented in iRLU, where
Indexed RLU iRLU

Absolute maximum RLU of test sample
Absolute maximum RLU of reference
Respiratory burst activity was induced when the rPfMSP119
antigen was coated onto the assay plate at a concentration 	5
g/mL, whereas the same concentrations of antigen present
in solution failed to induce a response (Fig. 1B). Coated pro-
tein likely forms an array, not present when the antigen is in
solution, which causes FcR on the neutrophil surface to colo-
calize and thus, initiate activatory -chain signaling and the
respiratory burst [44–46]. After coating separate wells of the as-
say plate with two different antigens (GST and PfMSP119-GST),
respiratory burst activity, induced by a panel of different sera, was
tested. The panel of sera included five different samples from
mice immunized with Ad-M PfMSP1 [29], P. falciparum Mz in
Freund’s adjuvant (thus containing PfMSP119, as well as many
other antigens), Ova [32], a transmission-blocking malaria vac-
cine candidate Pfs25 [30], and GST, as well as serum from
nonimmunized mice (naive). Positive ADRB activity was in-
duced by sera only when the immunization antigen matched
the antigen coated onto the assay plate (Fig. 1C), confirming
the specificity of the assay. Additionally, the magnitude of the
iRLU response decreased with decreasing coating antigen con-
centration (Fig. 1B), increasing serum dilutions (Fig. 1D), and
reduced cell numbers in each well (Fig. 1E). As such, a set of
assay conditions was established for further experiments, as
follows: antigen coated on the assay plate at 10 g/mL, serum
diluted 1:100 in PBS, and 50 L neutrophils added to each
well at 1  107 PMNs/mL. The use of maximal assay condi-
tions with a mid-range serum dilution (1:100) ensured that
both higher and lower assay responses could be detected for
test sera. With the use of these assay conditions and a
PfMSP119-GST-coated plate, assay variability was also deter-
mined. To assess intra-assay variability, a single pool of serum
derived from eight Ad-M PfMSP1-immunized BALB/c mice
was tested for induction of ADRB activity in eight separate
wells with neutrophils from a single donor mouse on each of 2
days. Interassay variability was determined by assessing ADRB
activity elicited by serum from each of the eight Ad-M PfMSP1-
immunized BALB/c mice on 6 different days (i.e., with a dif-
ferent neutrophil donor each day). Whereas intra-assay vari-
ability was not significant (two-way ANOVA F7,70.70, P0.67;
Fig. 1F), there was significant interassay variability (two-way
ANOVA F5,5423.08, P0.0001; Fig. 1G), although assay re-
peat (or different neutrophil donor) accounted for 5% of
the observed variance compared with 93%, resulting from
differences among the vaccine response in the test samples, as
determined by R2 analysis.
Role of FcR-mediated pathways in ADRB induction
The role of FcR-mediated pathways in inducing ADRB activity
was investigated using / and FcRIIb knockout
(CD32b/) mice. The number of neutrophils added to each
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well was kept constant between groups by counting the num-
ber of cells using a hemocytometer and assessing the percent-
age purity of neutrophils by Giemsa-stained slide, before ad-
justing accordingly. In this case, ADRB activity was measured
against PyMSP119-GST protein (using serum from mice immu-
nized with PyMSP1-based vaccines). The response induced by
neutrophils from WT mice in response to serum of BALB/c
mice, immunized i.m. with Ad-M PyMSP142 (median0.62
iRLU), was ablated when using neutrophils enriched from the
bone marrow of / mice (median0.06, P0.03; Fig. 2A).
Additionally, preincubation of WT neutrophils with anti-
CD16/32 mAb ablated their ability to induce ADRB activity
(Fig. 2B). On the other hand, neutrophils isolated from the
bone marrow of C57BL/6 mice lacking the inhibitory FcRIIb
were able to induce higher ADRB (median2.40 iRLU) than
those isolated from WT mice (median1.00 iRLU, P0.03;
Fig. 2C). Thus, it appears that ADRB activity is dependent on
FcR-mediated pathways; in particular, common -chain signal-
ing is necessary while regulation occurs via CD32b. Further-
more, given that mice lack CD32a [47–49] (the activatory
FcRII) and given the ablation of ADRB with anti-CD16/32
mAb, CD16/FcRIII appears likely to mediate ADRB induc-
tion in the mouse system.
Role of IgG isotypes in ADRB induction
To determine the contribution of different IgG isotypes to
ADRB induction, chimeric mouse IgG1 and IgG2a mAb
against the C1 epitope of PfMSP119 were expressed in HEK293
and CHO cell lines, respectively [35]. Purified antibodies of
each isotype at 8.3 g/mL induced indistinguishable levels of
ADRB activity against PfMSP119-GST (Fig. 2D). Additionally,
mice immunized i.m. with a PyMSP142 adenovirus prime
PyMSP119-GST protein-in-AdjuPhos boost regime (AP) or a
three-dose PyMSP119-GST protein-in-AdjuPhos regime (PPP)
[32] induced the same total IgG titer against PyMSP119, as
measured by end-point ELISA (Fig. 2E) but different profiles
of IgG isotypes (Fig. 2F). AP immunization resulted in a bal-
anced isotype response with equivalent induction of IgG1 and
Figure 1. Protein ADRB assay optimization. Assay variables were assessed using serum from Ad-M PfMSP1-immunized BALB/c mice and neutro-
phils enriched from the bone marrow of naive BALB/c mice. Plates were coated with 10 g/mL PfMSP119-GST protein, incubated with serum di-
luted 1:25 in PBS, and assayed with 50 L neutrophils/well at 1  107 PMNs/mL unless stated otherwise. (A) Representative flow plot of granulo-
cyte cell preparation used in the assay after enrichment for neutrophils (also see Supplemental Fig. 2). (B) ADRB activity induced by immune sera
against PfMSP119-GST protein in solution or coated onto a plate at decreasing concentrations. (C) The assay plate was coated with GST or
PfMSP119-GST recombinant protein at 10 g/mL. Bars indicate ADRB (all indexed against PfMSP1-positive sera on a PfMSP119-GST-coated plate)
induced by sera, taken from mice immunized with PfMSP1, P. falciparum Mz in Freund’s adjuvant (Mz), Ova, Pfs25, GST, or with no prior immuni-
zation (Naïve). (D) ADRB induction by anti-PfMSP1 sera at increasing serum dilutions (points represent mean  sem of six independent samples)
and (E) at a constant serum dilution of 1:100 with decreasing numbers of cells/well (50 L cells added at presented cell number/mL). (F) Serum
pooled from six Ad-M PfMSP1-immunized mice was tested in eight replicate wells on 2 days to assess intra-assay variability. (G) Serum from eight
Ad-M PfMSP1-immunized mice and one naive mouse was tested on 6 separate days in the assay to assess interassay variability. In all panels, bars,
and points represent mean of two assay replicates for each sample unless stated otherwise.
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IgG2a. In contrast, PPP immunization resulted in an IgG1-
dominated response with negligible levels of IgG2a being in-
duced, as shown previously for the AdjuPhos adjuvant [32].
ADRB activity was assayed using serum from mice immunized
with these two vaccination regimes, and no difference was ob-
served (P0.39; Fig. 2G), in agreement with the epitope-
matched chimeric mAb. These data suggest that the mouse
IgG1 and IgG2a isotypes can both elicit equivalent ADRB activ-
ity from neutrophils.
FcRs and efficacy against P. yoelii challenge
One of the goals of using this assay was to assess the ability of
activity measured in the assay to associate with protective effi-
cacy against blood-stage malaria infection. The previous data
showed that ADRB activity was dependent on FcR signaling in
the mouse model. Given that it is well-established that
PyMSP1-based vaccine efficacy in the P. yoelii blood-stage chal-
lenge model is antibody-mediated [28, 50], the impact of FcR
modifications on challenge outcome in vaccinated and P. yoelii-
infected mice was assessed. Vaccine doses were chosen based
on prior experience with this model to allow for improved or
reduced vaccine efficacy to be observed. Immunization i.m.
with Ad-M PyMSP142 induced the same levels of anti-PyMSP119
antibodies in WT and / BALB/c mice at all time-points
(Fig. 3A). The presence or absence of FcR signaling thus had
no impact on viral vectored vaccine antibody immunogenicity.
All mice were challenged subsequently with 104 lethal P. yoelii
strain YM pRBCs. The rate of survival was similar between WT
and / groups in vaccinated and naive, nonimmunized con-
trol groups (Fig. 3B). AUC analysis of Days 3–5 parasitemias
for vaccinated mice showed no difference in parasite burden
between WT and / groups (P0.31), although naive mice
showed a higher parasite burden in the WT group
(P0.002; Fig. 3C), indicating a small but significant delay
in the knockouts reaching end-point parasitemia. Similarly,
in WT and CD32b/ C57BL/6 mice, antibody levels in-
duced by vaccination did not differ at any time-point be-
tween groups (Fig. 3D), nor was there any difference in
challenge outcome survival rates (Fig. 3E) or parasite bur-
den (AUC analysis for Days 3–5) for vaccinated (P0.93) or
naive groups (P0.13; Fig. 3F).
Thus, despite the inability of / mice to induce ADRB,
the vaccinated mice were still able to control parasitemia, indi-
cating that vaccine-induced efficacy in this model is unlikely
ADRB- or FcR-dependent. Likewise, the ability of CD32b/
mice to induce higher ADRB did not enhance vaccine-medi-
ated control of parasitemia. Taken together, all of these initial
Figure 2. Role of FcR-mediated pathways
in ADRB induction. Serum was collected
from BALB/c and C57BL/6 mice immu-
nized with Ad-M PyMSP142 or BALB/c
mice immunized with three doses of
PyMSP119-GST with AdjuPhos (PPP) or
one dose AdHu5-PyMSP142, followed by
one dose PyMSP119 with AdjuPhos (AP).
Assays were set up with 10 g/mL
PyMSP119-GST-coated plates, 50 L/well
neutrophils at 1  107 PMNs/mL and se-
rum diluted 1:100 in PBS run in duplicate
wells. Neutrophils were isolated from the
bone marrow of WT BALB/c and C57BL/6 mice, plus / and CD32b/ mice on the same genetic backgrounds, respectively. ADRB induc-
tion was assessed by: (A) BALB/c and / PMNs in response to sera from BALB/c mice immunized with Ad-M PyMSP142; (B) BALB/c PMNs
in response to sera from Ad-M PfMSP1-immunized or naive BALB/c mice (on a PfMSP119-GST-coated plate), where PMNs had been preincu-
bated with neutrophil buffer (black), control rat IgG (gray), or anti-CD16/32 mAb (white); (C) C57BL/6 and CD32b/ PMNs in response to
sera from C57BL/6 mice immunized with Ad-M PyMSP142; and (D) BALB/c PMNs in response to mouse isotype-specific chimeric anti-PfMSP119
mAb at 8.3 g/mL (on a PfMSP119-GST-coated plate). For mice immunized with AP and PPP regimes, (E) PyMSP119 end-point ELISA titers
against PyMSP119-IMX108-coated plates, (F) IgG1 and IgG2a isotype-specific ELISA titers against the same protein as total IgG, and (G) ADRB
activity using BALB/c PMNs were determined. *P  0.05 (Wilcoxon matched-pairs signed-rank test). Bars and points represent means of two rep-
licates for each sample, and medians on dot plots are shown, represented by lines.
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Figure 3. P. yoelii challenge of /and CD32b/ mice. Challenge out-
come in BALB/c, /, C57BL/6, and CD32b/ mice was investi-
gated. All mice (n6/group) were immunized i.m. with Ad-M
PyMSP142. PyMSP119 ELISA titers were determined in (A) BALB/c and
/ mice and (D) C57BL/6 and CD32b/ at 14, 55, and 70 days
post adenovirus immunization (MVA boost occurred on Day 56). At Day
70, all mice were challenged i.v. with 104 P. yoelii YM pRBCs. Blood-
stage parasitemia is reported as the percentage of infected RBCs over
time in (B) BALB/c and / groups and (E) C57BL/6 and CD32b/
groups. AUC analysis for Days 3–5 (D3–5) was conducted on (C) parasitemia plots for BALB/c and / mice and (F)
plots from C57BL/6 and CD32b/ mice. Lines on dot plots represent median values. †Animal being culled after reach-
ing the humane end-point of 50% blood-stage parasitemia.
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protection data suggested that FcR-mediated effector functions
(including ADRB activity, as measured in vaccinated mice) are
not essential in determining the outcome of primary challenge
in the murine P. yoelii model, neither in vaccinated nor con-
trol mice.
Assaying ADRB with coated antigen versus whole Mz
The ADRB assay methodology established above is not limited
to use with the MSP119 antigen but can be used to assess func-
tional antibody activity against any antigen under study once
coated onto the plate [43, 51]. It also does not permit assess-
ment or comparison of the effectiveness of ADRB induction by
antibodies binding to different antigens, as presented in the
context of the intact Mz itself. We therefore decided to assess
the possibility of using whole malaria parasites in the assay
rather than an array of rMSP119 protein. Whreas the vaccines
used above induce serum antibodies that show ADRB re-
sponses against MSP119 protein coated onto the plate, it was
wholly possible that the same vaccines do not induce func-
tional ADRB from neutrophils via opsonization of Mz. The
first challenge dataset supported this hypothesis, indicating
that there was no association between ADRB activity, as mea-
sured in the assay against PyMSP119 (Fig. 2A and C) and vac-
cine efficacy. As such, the assay was established to assess ADRB
activity in response to P. yoelii YM Mz (PyPEMS) and was
shown to be reproducible in the same fashion as the PyMSP119
assay (Supplemental Fig. 3).
To investigate whether anti-PyPEMS ADRB was induced by
immunization, 12 WT BALB/c mice were first immunized i.m.
with Ad-M PyMSP142 and then challenged with a nonlethal
strain of P. yoelii (17XNL). Two weeks after the boost (time of
challenge), sera from immunized mice showed PyMSP119- and
PyMSP133-specific antibody responses, as measured by stan-
dardized ELISA. These responses were boosted slightly after
challenge for PyMSP119 (P0.002) and PyMSP133 (P0.004;
Fig. 4A). However, following vaccination, the sera did not lead
to a significant induction of ADRB activity against PyPEMS
(Fig. 4B, white bars). In contrast, following challenge with 106
Py17XNL pRBCs and parasite clearance, serum from five of 12
mice did induce detectable levels of ADRB activity against P.
yoelii Mz (Fig. 4B, black bars).
This induction of ADRB activity could be a result of boost-
ing pre-existing antibody titers against PyMSP142 or an induc-
tion of antibody responses against de novo parasite antigens. It
seemed more likely that the resultant activity is a result of rec-
ognition of new antigens, as there was no correlation between
PyMSP119- or PyMSP133-specific total IgG ELISA titer and an-
ti-Mz ADRB activity after challenge (r0.44, P0.15; r0.07,
P0.86, respectively) or when the pre- and postchallenge data
were pooled (PyMSP119: r0.09, P0.67; PyMSP133: r0.04,
P0.85; Fig. 4C).
ADRB activity and secondary parasite exposure
The above data suggested that functional anti-Mz ADRB activ-
ity was detectable in the P. yoelii model following vaccination
and a nonlethal primary parasite exposure. We therefore
sought to assess whether anti-Mz ADRB activity could contrib-
ute to protective efficacy following secondary parasite expo-
sure, given the activity in serum was now detectable. To ad-
dress this, in addition to the 12 immunized WT mice de-
scribed in Fig. 4, six / mice were immunized and
challenged with nonlethal parasites in the same manner,
whereas a matching 18 mice were challenged without prior
immunization (Fig. 5A). Following primary challenge, AUC
analysis of blood-stage parasitemia demonstrated that vaccina-
tion achieved significant protection in the WT (n12 vs. 12;
P0.001) and / (n6 vs. 6; P0.004) groups. Intriguingly,
/ mice also controlled parasitemia better than WT mice in
Figure 4. PyMSP1 ELISAs and PyPEMS ADRB. Twelve WT BALB/c mice were immunized i.m. with Ad-M PyMSP142 before being challenged i.v.
with 106 P. yoelii 17XNL pRBCs. (A) PyMSP119 () and PyMSP133 (Œ) antibody titers were assessed by standardized ELISA in mice, 2 weeks after
boost (1 day before challenge; C1), and 55 days after challenge (C55). PyMSP119 titers for serum from three naive, control mice are also
shown. (B) ADRB activity induced by BALB/c PMNs (1107 PMN/mL) against PyPEMS was determined using sera (neat) from the C1 (white
bars) and C55 (black bars) time-points. Background cutoff, defined as 3 sd above the mean of the level of ADRB activity induced by naive
BALB/c mouse serum (n4) in the same assay (gray bar), is indicated by the dotted line. (C) PyMSP119 () and PyMSP133 (Œ) ELISA titers were
plotted against pre- and postchallenge anti-PyPEMS ADRB activity. Lines on dot plots represent medians, bar charts represent mean of two assay
replicates, and Spearman rank correlations (r) shown on scatter plot for PyPEMS ADRB with PyMSP119 (solid line) and PyMSP133 (broken line)
ELISA titers.
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vaccinated (P0.004) and naive (P0.002) groups (Fig. 5B).
On Day 55, after the primary P. yoelii 17XNL challenge (be-
tween 35 and 49 days postparasite clearance) and in agree-
ment with the previous observation, serum from 18/35 mice
elicited positive ADRB activity against P. yoelii YM Mz (when
tested with neutrophils from WT mice; Fig. 5C). The induc-
tion of this serum activity was comparable and equally distrib-
uted across the immunized and nonimmunized groups, again
suggesting that this activity was independent of PyMSP142 vac-
cine-induced responses. We also hypothesized that ADRB in-
duction may occur as a result of accumulative parasite expo-
sure, in which case, ADRB activity against P. yoelii Mz would be
expected to correlate with parasite exposure, as measured by
AUC analysis of blood-stage parasitemia; however, no such cor-
relation was seen (r0.08, P0.66; Fig. 5D).
To ascertain whether an induction of anti-Mz ADRB activity
had any effect on challenge outcome, all 35 mice were rechal-
lenged 8 weeks after the initial nonlethal challenge with 106
lethal P. yoelii YM pRBCs. One day before challenge and 3 days
after challenge, one group of six mice in each of the immu-
nized and nonimmunized WT groups was injected i.p. with 0.5
mg 1A8 mAb, a PMN agent [41, 42]. All other mice received
a comparable dose of control rat IgG at the same time-points.
PMN was confirmed in the blood and the spleen of addi-
tional control mice at Days 1 and 7 postchallenge by flow cy-
tometry. The blood neutrophil population was depleted by
90% over this time-course. On Day 1 postchallenge, a high
level of depletion was visible in the spleen (80%); however,
this population had largely reappeared by Day 7 (Fig. 6A).
Following lethal secondary challenge, 66% of all mice were
sterilely protected, with no parasites being observed in the
blood over the course of the monitoring period. There was no
difference in parasite burden among the three immunized
groups (WT, PMN, and /), as determined by one-way
ANOVA (P0.40; Fig. 6B), although it may remain impossible
to ascertain potential differences in the face of such high lev-
els of protective efficacy afforded by the preceding vaccination
and P. yoelii 17XNL challenge. On the other hand, there was a
significant difference among nonimmunized groups
(P0.008), as a result of a greater parasite burden experi-
enced by / mice than nonimmunized WT mice, as mea-
sured by AUC between Days 3 and 6. PMN mice, in contrast,
experienced a similar infectious burden to nondepleted WT
mice (Dunn’s multiple comparison test; Fig. 6B). It should
also be noted that all mice that received 1A8 treatment had
completely cleared and/or prevented parasitemia by Day 6
(during the time of maximum PMN). In fact, only two of 11
mice treated with 1A8 developed any detectable parasitemia
following secondary challenge.
Thus, overall, it appears that the FcR common -chain sig-
naling may play a role in the control of parasitemia during
secondary infection of some mice that did not receive a prior
effective vaccine, although this control is not mediated by neu-
trophils. It should also be noted that the / mice here, ex-
periencing reduced control of secondary parasitemia, exhib-
ited the lowest levels of parasite exposure (and the highest
degree of innate protection) in the preceding P. yoelii 17XNL
challenge (Fig. 5A and B). However, the induction of serum
anti-PyPEMS ADRB activity postchallenge (Fig. 5C) was compa-
rable with the WT-nonimmunized mice, suggesting similar in-
duction of antimalarial responses in these mice, despite the
slightly lower parasite burden in the primary challenge.
Despite the lack of association between ADRB activity and
challenge outcome in this model, we also assessed ADRB activ-
ity following the secondary P. yoelii exposure in the 13 mice
showing the highest ADRB response after primary challenge.
Serum ADRB activity was enhanced by parasite exposure (Fig. 7),
showing higher levels in comparison with after primary chal-
Figure 5. ADRB and P. yoelii malaria challenge. BALB/c or / mice were immunized i.m. with Ad-M
PyMSP142 and challenged 2 weeks later with 10
6 P. yoelii 17XNL pRBCs. (A) Blood-stage parasitemias in
BALB/c and / groups are reported as the percentage of infected RBCs. (B) AUC analysis of para-
sitemia between Days 3 and 20 was conducted for naive/nonvaccinated () and immunized (Œ) groups.
(C) Fifty-five days after challenge, ADRB activity of mouse serum against PyPEMS was assessed as before.
(D) Postchallenge anti-PyPEMS ADRB activity was plotted against AUC, calculated between Days 3 and 20.
Lines on dot plots represent medians, bar charts represent mean of two replicates for each sample, and
line on scatter plot represents Spearman rank correlation. †Animal being culled after reaching the hu-
mane end-point of altered behavior due to treatment.
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lenge (Fig. 5C). To address antigen-specificity further in the
assay, we depleted sera using the rPyMSP1 proteins (Fig. 7). As
expected, assays using plates coated with rPyMSP119 or
PyMSP133 protein demonstrated an antigen-specific effect of
antibody depletion upon ADRB activity (Supplemental Fig. 1).
When tested using PyPEMS, depletion of PyMSP119 antibodies
did not significantly decrease the sera’s ability to induce ADRB
activity (Friedman test; Dunn’s multiple comparison test); how-
ever, PyMSP133 antibody depletion reduced ADRB activity
against PyPEMS similarly in immunized and nonimmunized
mice, suggesting that after secondary challenge, the PyMSP133
region of the PyMSP1 antigen is a target of ADRB-inducing
antibodies.
DISCUSSION
The blood-stage malaria vaccine field has often struggled as a
result of the lack of in vitro assays with which to screen and
assess possible subunit vaccine candidate antigens. Whereas
IgG responses to Mz antigens have, in some cases, been corre-
lated with clinical immunity following natural malaria expo-
sure [52–56], little has been done to characterize the func-
tional mechanisms of these antibodies. It is important to note
the distinction between effector mechanisms, which may act
against the invasive Mz form of the parasite, versus subse-
quently infected RBCs, which express parasite-derived proteins
on their surface. Phagocytic uptake of the latter has been
widely described and assayed [57]; however, in the case of P.
falciparum vaccine development, such RBC surface antigens are
widely thought to be too polymorphic (in most instances) to
be realistic vaccine targets. In the context of anti-Mz immunity,
the assays of GIA and ADCI have been described previously
[11, 17], along with assays of Mz phagocytosis using THP-1
[58] cells or neutrophils [59]. The relationship of the latter
with clinical outcome in naturally exposed individuals remains
to be established. The assay of ADRB activity using human
neutrophils has been reported to associate with clinical immu-
nity in an endemic population in Senegal [24]. Here, we re-
port on an assessment of the ADRB assay in the mouse model
and apply it, for the first time, to the field of malaria vaccine
development.
Initial work confirmed antigen specificity and established
the assay parameters when using recombinant antigen arrayed
on the plate. These assay conditions used a minimal volume of
Figure 6. The role of common -chain signaling and neutrophils in
protection against secondary exposure to P. yoelii. BALB/c or /
mice were immunized i.m. with Ad-M PyMSP142, challenged at Week
10 with 106 P. yoelii 17XNL pRBCs and then rechallenged at Week 18
with 106 P. yoelii YM pRBCs. One day before and 3 days after second-
ary challenge, six BALB/c and six / mice were given 0.5 mg 1A8
i.p. (PMN), and all other mice—WT and /—were given 0.5 mg
i.p. control rat IgG. (A) Representative flow plots showing granulo-
cytes from the blood and spleen of BALB/c mice treated in parallel
with challenged mice on Days 1 and 7 following 1A8 or control rat
IgG treatment. Plots thus represent inferred PMN in challenged
mice. Flow data acquisition was normalized by setting stopping gates at
104 or 105 CD8 cells for blood and spleen samples, respectively.
Boxes and numbers indicate the neutrophil population and their per-
centage make-up of the granulocyte population. (B) AUC analysis of
parasitemia for Days 3–6 following secondary challenge of nonimmu-
nized () and immunized (Œ) groups. Lines on dot plot represent
medians.
Figure 7. Contribution of anti-PyMSP142 antibodies to post-secondary
challenge anti-PyPEMS ADRB activity. BALB/c or / mice were im-
munized i.m. with Ad-M PyMSP142 and challenged as in Fig. 6. Four-
teen days postsecond challenge, anti-PyPEMS ADRB activity was as-
sessed in mouse serum preincubated with PBS (no depletion; black)
or depleted of PyMSP119 (gray)- or PyMSP133 (white)-specific antibod-
ies. Checkered bars (, positive reference serum) represent back-
ground ADRB activity of depleted sera without any antigen coated
onto the plate. Results with naive BALB/c mouse serum are also
shown.
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serum and allowed for an increase and decrease in ADRB ac-
tivity to be observed with minimal intra-assay variability. Al-
though some interassay variability was noted when repeatedly
using the same sample on freshly isolated PMNs, the inherent
differences among individual samples were greater and thus,
reliably observed among assay replicates. This mouse ADRB
assay also allowed for the roles of FcR-mediated antibody sig-
naling to be assessed. Mice have three classes of activatory
FcRs (I, III, IV) that signal through the common -chain
ITAMs [47]. The work reported here has shown a dependency
on these receptors for ADRB induction, given ablation of this
activity when using PMN from / mice. More specifically,
we conclude that ADRB activation is FcRIII (CD16)-mediated,
given that FcRI (CD64) is not constitutively expressed on
mouse neutrophils [60, 61] and thus, is unlikely to contribute
to ADRB [a result supported by the ablation of ADRB activity
by a CD64-irrelevant mAb (anti-CD16/32)] and that mice lack
the activatory FcRIIa (CD32a) [47, 49]. ADRB induction,
however, is not only induced by CD16 but also, is regulated by
FcRIIb (CD32b), given that enhanced levels of activity were
observed when using PMN from CD32b/ mice. It is unlikely
that CD32b regulation results from interference with other
antibody-FcR binding but rather, results from intracellular
ITIM signaling, which initiates the recruitment of Src homol-
ogy 2 domain-containing inositol phosphatase and impedes
CD16 signal transduction [62–64].
The human IgG1 and IgG3 cytophilic isotypes have been
reported to be essential for the induction of ADCI activity
against the P. falciparum parasite and specific antigens such as
MSP3 [15, 65, 66], whereas a human IgG1 mAb against
PfMSP119, but not an epitope-matched IgA, has been reported
to protect against transgenic P. berghei in humanized mice [21,
67]. Similarly, the cytophilic mouse isotype IgG2a has been
reported to be important for protective immunity against
blood-stage P. berghei [68] and P. yoelii [69, 70]. However, in
our hands, the IgG1 and IgG2a isotypes appeared comparable
in their ability to induce ADRB activity from PMN—either us-
ing serum skewed toward specific isotype profiles by use of dif-
ferent vaccine immunization regimes [32] or by using chime-
ric epitope-matched mAbs [35]. We were unable to express
sufficient quantities of chimeric epitope-matched mouse IgG2b
and IgG3 (data not shown), and so, it remains to be deter-
mined whether these isotypes could also function in a similar
manner. Notably, mAb of both of these isotypes have been
shown to afford efficacy against blood-stage P. yoelii [19, 71].
However, given that mouse IgG1 and IgG2a are reported to
signal via CD16 [47, 72] and tend to be the dominant IgG iso-
types in serum, these data suggest that total antigen-specific
IgG antibody titer in mice is likely to correlate closely with
ADRB induction.
In addition to using the ADRB assay to assess antibody-re-
ceptor interactions, mouse malaria models provide an invalu-
able tool for assessing protective outcome. Initial studies indi-
cated that serum from PyMSP142-vaccinated mice could reli-
ably induce ADRB activity from neutrophils in the assay when
rPyMSP119 antigen was arrayed on the plate. Despite neutro-
phils from / mice lacking the ability to produce ROS in
the context of the ADRB assay and CD32b/ mouse neutro-
phils having an increased ability to produce ROS, no differ-
ence was seen in primary P. yoelii challenge outcome following
immunization of these mice (which mounted comparable im-
mune responses with WT controls in response to viral-vector
immunization, as seen in a previous study [26]). We also ob-
served little difference in the protective outcome between non-
immunized WT and CD32b/ C57BL/6 mice following lethal
P. yoelii challenge, unlike that reported for P. chabaudi infec-
tion on the BALB/c background [22]. However, it became
apparent following further investigation that these immunized
animals did not have antibodies capable of inducing ADRB
against PyPEMS. ROS production by PMNs has been widely
tested in the literature using such methodology [43, 51, 73–
75], but these data highlight the importance of using native
parasites in such an assay set-up. Previous work on ADCI activ-
ity suggests that it is not overly surprising that C-terminal
MSP1 (MSP142) immunization did not induce antiparasite cel-
lular activation, given that investigation of antibody-dependent
monocyte activation has identified other antigenic targets,
such as glutamate-rich protein [76], serine repeat protein
[77], MSP3 [78], and MSP1 block 2 [79]. As a result of the
likely similarity in antibody action between ADCI and ADRB,
the aforementioned targets may also represent those playing
dominant roles in eliciting anti-Mz ADRB activity. The lack of
detectable anti-PyPEMS ADRB activity post-PyMSP142 vaccina-
tion was thus in agreement with the challenge data showing
no bearing on an initial challenge in the knockout mice, and
moreover, these data would suggest that the mechanism by
which the PyMSP142 vaccine protects is not FcR-mediated. Im-
portantly, these data also suggested that anti-PyMSP119 IgG
responses may not be sufficient to induce ADRB activity, which
would make sense, given the closeness of this moiety to the
parasite surface and the fact the antigen may not be accessible
to antibodies until the MSP1 molecule is processed during
RBCs’ invasion [80, 81]. However, it remained possible that
throughout the course of a challenge infection, the animal
could acquire de novo antiparasite antibodies capable of in-
ducing ADRB, but this would be unlikely, given the short in-
fection period investigated here with the highly lethal YM
strain of P. yoelii. We thus switched to the use of a nonlethal
model to assess postchallenge antibody responses.
In this case, following a nonlethal strain 17XNL primary in-
fection, almost 50% of mice acquired anti-PyPEMS serum
ADRB activity. This induction was irrespective of prior
PyMSP142 vaccination status and did not correlate with anti-
body titers against PyMSP119 or PyMSP133, again suggesting
the activity to be independent of this antigen. However, it was
then possible to reassess the importance of FcR and anti-
PyPEMS ADRB activity in protection against secondary P. yoelii
challenge. In this case, when mice were depleted of neutro-
phils, they were still able to control parasitemia, suggesting
that these cells are not key effectors in controlling secondary
infection in the P. yoelii model, despite measurable ADRB ac-
tivity. Nevertheless, data from nonvaccinated / mice in the
same experiment alluded to a contribution of FcR-mediated
signaling in controlling secondary exposure to P. yoelii malaria
in mice and the possibility that this efficacy is mediated
through a non-neutrophil cell group. There have been numer-
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ous reports of monocytes playing an important role in parasite
killing through ADCI [9, 14, 16, 82, 83] or phagocytosis of in-
fected RBCs. It would seem possible that in the absence of vac-
cine-induced responses against PyMSP142, other antigen speci-
ficities acting against the Mz and/or infected RBC may play a
more dominant role in effective immunity.
Overall, our data support the evidence that P. yoelii malaria
infection is controlled largely by FcR-independent activity [18],
especially given that both immunized and nonimmunized
/ mice performed better than WT littermate controls in
the challenge experiments. Interestingly, ADRB serum activity
was again enhanced by secondary infection (with a likely in-
creased contribution from anti-PyMSP133 antibodies). Al-
though no association was established with protection against
P. yoelii, these data suggest that other antigen targets of anti-
PEMS ADRB activity remain to be established. They also sug-
gest that this activity increases with repeated malaria exposure,
thus adding weight to the original report of association of this
activity with clinical immunity against P. falciparum [24].
The development of new, functional antibody assays remains
vital for preclinical malaria vaccine development. With relative
ease, the principles of this assay could be transferred to assess-
ment of ADRB activity using P. falciparum PEMS and human
neutrophils, thus overcoming the limitations in extrapolating
results from P. yoelii challenges in mice to humans and P. falci-
parum. Such research should provide important, new avenues
for blood-stage malaria vaccines, complementing the develop-
ment of GIA-based vaccines; however, further studies will be
required to address whether this mechanism is directly con-
tributing to immunity in humans, unlike in this mouse model.
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